Betamethasone disodium phosphate
(Synonyms: 倍他米松磷酸钠,Betamethasone 21-phosphate disodium salt; Vista-Methasone) 目录号 : GC65398
A synthetic corticosteroid
Cas No.:151-73-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Betamethasone is a synthetic corticosteroid.1 In vivo, betamethasone (5 mg/kg) reduces bronchoalveolar lavage fluid (BALF) matrix metalloproteinase-2 (MMP-2) and MMP-9 activities, TNF-α levels, and neutrophil number in a mouse model of LPS-induced lung injury. Prenatal administration of betamethasone (0.1 mg/kg) improves neonatal lung function but decreases hippocampal and corpus callosum neuron density and induces motor function deficits in a rabbit model of late preterm birth.2 It also extends gestational length in a rat model of preterm labor induced by high mobility group protein B1 (HMGB1).3 Formulations containing betamethasone have been used in the treatment of inflammatory skin conditions and prenatally to promote fetal lung maturation.
1.Corbel, M., Lagente, V., Théret, N., et al.Comparative effects of betamethasone, cyclosporin and nedocromil sodium in acute pulmonary inflammation and metalloproteinase activities in bronchoalveolar lavage fluid from mice exposed to lipopolysaccharidePulm. Pharmacol. Ther.12(3)165-171(1999) 2.van der Merwe, J., van der Veeken, L., Inversetti, A., et al.Neurocognitive sequelae of antenatal corticosteroids in a late preterm rabbit modelAm. J. Obstet. Gynecol.226(6)850.e851-850.e821(2022) 3.Galaz, J., Romero, R., Arenas-Hernandez, M., et al.Betamethasone as a potential treatment for preterm birth associated with sterile intra-amniotic inflammation: A murine studyJ. Perinat. Med.49(7)897-906(2021)
| Cas No. | 151-73-5 | SDF | Download SDF |
| 别名 | 倍他米松磷酸钠,Betamethasone 21-phosphate disodium salt; Vista-Methasone | ||
| 分子式 | C22H28FNa2O8P | 分子量 | 516.4 |
| 溶解度 | 储存条件 | 4°C, away from moisture | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9365 mL | 9.6824 mL | 19.3648 mL |
| 5 mM | 0.3873 mL | 1.9365 mL | 3.873 mL |
| 10 mM | 0.1936 mL | 0.9682 mL | 1.9365 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Determination of Betamethasone disodium phosphate in the in vitro media of PLGA microspheres by high-performance liquid chromatography
J Pharm Biomed Anal 2002 May 15;28(3-4):629-35.PMID:12008142DOI:10.1016/s0731-7085(01)00667-7.
Betamethasone disodium phosphate is a kind of corticosteroid, which is commonly used in the intralesional treatment of keloids. In this work, polymeric microspheres loaded with Betamethasone disodium phosphate were fabricated to design a sustained-release system. A validated HPLC technique for determination of Betamethasone disodium phosphate in in vitro media of the polymeric microspheres has been developed. The operation conditions were optimized. The analytical column was ZORBAX Bonus-RP column with 4.6 x 150 mm ID and a particle size of 5 microm. The mobile phase consisted of acetonitrile-0.01% phosphoric acid water solution (40:60, v/v). The flow rate was 1.0 ml/min and injection volume was 50 microl. The elutes were detected at 240 nm. Linearity, repeatability, inter- and intra-assay precision and accuracy of the method were evaluated. The liner range was obtained in a concentrated range of 20-1000 microg/ml, with a coefficient of correlation r=0.999978. The limit of detection for Betamethasone disodium phosphate in the in vitro test samples was 0.25 microg. Recovery of Betamethasone disodium phosphate from the in vitro test samples was 99.7+/-5.2% (mean+/-SD). Stability of Betamethasone disodium phosphate at different pH values and temperatures were also investigated.
Anaphylaxis induced by intramuscular Betamethasone disodium phosphate: reflections on a clinical case
Int J Immunopathol Pharmacol 2007 Apr-Jun;20(2):387-91.PMID:17624252DOI:10.1177/039463200702000220.
Glucocorticoids could be responsible for allergic symptoms correlated to an Ig-E mediated hypersensitivity mechanism. We describe the case of an anaphylactic reaction in a professional nurse, occurring after an intramuscular administration of Betamethasone. After performing skin prick tests, intramuscular tests and patch tests we concluded that the patient had Ig-E mediated sensitization. She was prescribed oral Prednisone and Deflazacort and shows good tolerance of these drugs. This demonstrates that in these patients it is possible to administrate glucocorticoids without the changes in the sites indicated by Wilkinson. Nevertheless, our patient showed a negative allergy test for Dexamethasone disodium phosphate, and in those patients sensitized to fluorinated glucocorticoids, tolerance to other glucocorticoids is not so easily predictable as in patients with hypersensitivity to first generation steroids or in corticosteroid contact dermatitis, according to the four patterns of cross-reactivity proposed by Coopman and Dooms-Goossens.
[Treatment of generalized cutaneous lichen planus with dipropionate and Betamethasone disodium phosphate: an open study of 73 cases]
Ann Dermatol Venereol 2007 Mar;134(3 Pt 1):237-40.PMID:17389847DOI:10.1016/s0151-9638(07)91815-3.
Objective: The aim of this study was to evaluate the efficacy of treatment of generalized cutaneous lichen planus using dipropionate and Betamethasone disodium phosphate. Patients and method: A prospective study was conducted among patients presenting generalized cutaneous lichen planus consulting a dermatology service of Lomé teaching hospital in Togo (September 2003 to August 2005). Each patient included in our study reveived three injections of dipropionate and Betamethasone disodium phosphate every 2 weeks. Evaluation was done at 6 weeks, 3 months and 6 months. Results: 73 cases of generalized cutaneous lichen planus were included in our study. The sex-ratio (H/F) was 0.7. The average age of patients was 29.5 +/- 11.9 years. At six weeks: complete remission was 83.6% (61 cases) and partial remission was 8.2% with a failure rate of 8.2%. At 3 months, persistent complete remission was 58.9% vs. 23.3% relapse. At 6 months, relapse was 31.5%. No major side-effects were reported among our patients during the study period. Discussion: The study results suggest that dipropionate and Betamethasone disodium phosphate may constitute an alternative therapeutic approach in generalized cutaneous lichen planus. However these results require confirmation by a randomized trial over a longer period.